STAY UP TO DATE on new developments
Bipartisan Cancer Patient Equity Act (CPEA 2021) H.R.5377 Introduced by Rep. Butterfield (D-NC-01) and Rep. Bilirakis (R-FL-12): Advocacy Campaign Success of SHEPHERD Foundation on Behalf of Rare Cancer Patients
WASHINGTON, Sept. 28, 2021 /PRNewswire/ -- Congressmen G. K. Butterfield (D-NC-01) and Gus Bilirakis (R-FL-12), the driving political forces behind the realization of the Cancer Patient Equity Act (CPEA 2021), have been instrumental champions of the SHEPHERD Foundation's "Rare isn't Rare" Advocacy Campaign and bringing this impactful legislation to fruition. The SHEPHERD Foundation, a D.C.-based non-profit focused on providing industry-wide change for rare cancer diagnoses, has been a leading voice for the rare cancer community, petitioning for additional funding, treatments, expanded coverage, and a broader scope of how rare cancer is defined.
Read more here.
SHEPHERD Therapeutics Presents First Public Data at 2021 ESMO Congress Highlighting Ability of DELVE Computational Approach to Optimize Therapeutic Selection for Cancer Patients
BOSTON, Sept. 16, 2021 (GLOBE NEWSWIRE) -- SHEPHERD Therapeutics, a company dedicated to catalyzing lifesaving treatments for cancer patients, is pleased to present an e-poster of results from a computational approach to optimizing therapeutic selection for cancer patients using the Company’s proprietary precision-oncology DELVE platform, at the European Society for Medical Oncology (ESMO) Virtual Congress 2021. In this first public presentation of a DELVE analysis, DELVE was able to predict drug efficacy on cancer models and correctly select indications for existing therapies, supporting its utility in predicting new indications for cancer therapies.
Read more here.
The New Voices in Science, Engineering and Medicine Program announces its 2021-2023 cohort of 22 early-career leaders from academia, industry, government, and non-profit organizations.
The new members are rising stars in their fields and have been selected through a competitive review process out of nearly 300 applicants.
The New Voices program was launched by the National Academies of Sciences, Engineering, and Medicine in 2018 as an initiative to bring diverse perspectives from early-career U.S. leaders to important dialogues around how science, engineering, and medicine are shaping the global future. The program is made possible with support from the Gordon and Betty Moore Foundation.
Learn more here
No Warrior Left Behind
Cancer Wellness Magazine
by Britt Julious
July 23, 2021
For SHEPHERD Therapeutics founder David Hysong, “rare isn’t rare” is more than just a slogan when it comes to oncology. It is a battle cry rooted in his personal fight against cancer.
“We like to think about where we think the world will be in 10 years and then basically make that reality accessible now,” says David Hysong, founder and CEO of SHEPHERD Therapeutics.
Since founding the company in 2015 and launching its sister organization, SHEPHERD Foundation, Hysong has been on a mission to revolutionize the world of oncology, especially rare cancers. Utilizing a new program, Delve, which matches any cancer (or cancer patient) with the best therapeutics to target their diseases, SHEPHERD aims to leave no patient behind. But SHEPHERD Therapeutics’ mission is more than just noble for Hysong. It’s also personal.
Learn more here
Inspirational Women in STEM and Tech: Dr. Catharine Young of The SHEPHERD Foundation On The 5 Leadership Lessons She Learned From Her Experience
by Penny Bauder
June 24, 2021
As a part of my series about “Lessons From Inspirational Women in STEM and Tech”, I had the pleasure of interviewing Dr. Catharine Young.
Dr. Catharine Young is the former Senior Director of the Biden Cancer Initiative, now serving as Executive Director of the highly impactful SHEPHERD Foundation.
Fresh off the Biden campaign, Catharine was named Executive Director of the SHEPHERD Foundation, a separate vertical of SHEPHERD Therapeutics. SHEPHERD Therapeutics is a force for change in how rare cancers are diagnosed and treated. The SHEPHERD “Rare Isn’t Rare” approach has garnered the attention of big Pharma and oncologists across the globe. In her role as director of the Foundation, Catharine oversees the non-profit arm of SHEPHERD.
Read full article here